ApoB gene polymorphism (rs676210) and its pharmacogenetics impact on atorvastatin response among Iraqi population with coronary artery disease
Abstract Background Drug response is below genetic influence, proven by the genetic variants. Pharmacogenetics trials are performed in many diseases, including coronary artery disease. This study was designed to determine the genetic polymorphism (rs676210) Pro2739leu G > A in the lipid metabolis...
Main Authors: | Shaimaa Y. Abdulfattah, Salwa J. Al-Awadi |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-06-01
|
Series: | Journal of Genetic Engineering and Biotechnology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s43141-021-00193-4 |
Similar Items
-
ApoB100 and Atherosclerosis: What’s New in the 21st Century?
by: Dimitris Kounatidis, et al.
Published: (2024-02-01) -
Association of CELSR2, APOB100, ABCG5/8, LDLR, and APOE polymorphisms and their genetic risks with lipids among the Thai subjects
by: Manit Nuinoon, et al.
Published: (2023-02-01) -
Identification of apoB‐100 Peptide‐Specific CD8+ T Cells in Atherosclerosis
by: Paul C. Dimayuga, et al.
Published: (2017-07-01) -
Ellagic Acid Suppresses ApoB Secretion and Enhances ApoA-1 Secretion from Human Hepatoma Cells, HepG2
by: Ayana Ieda, et al.
Published: (2021-06-01) -
ApoB is superior to LDL-C or non-HDL-C as a lipid marker for predicting the presence and severity of atherosclerosis in female patients with myocardial infarction
by: Hui-Wen Zhang, MS, et al.
Published: (2017-05-01)